Two New Prostate Cancer Therapies Further Treatment Options

Two New Prostate Cancer Therapies Further Treatment Options
Treatment of metastatic castration resistant prostate cancer (mCRPC) has progressed throughout the years due to a number of advances in knowledge and understanding of the disease. Beginning with androgen deprivation therapy (ADT) as the standard of care due to the 1941 finding that prostate cancer regresses with androgen withdrawal, treatment has continually focused on androgen

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *